Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NCT06138821
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD/metabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity
- Liver Diseases
- Liver Fibrosis
- Liver Fat
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Dysfunction-Associated Steatohepatitis
- MASLD
- MASH
- Weight Loss
- Insulin Resistance
- Insulin Sensitivity
- Insulin Sensitivity/Resistance
- Metabolic Disease
- Diabetes
- Diabetes Mellitus, Type 2
- NASH With Fibrosis
- Non-Alcoholic Fatty Liver Disease
- Non Alcoholic Fatty Liver
- Non-alcoholic Steatohepatitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Pichamol Jirapinyo, MD, MPH
- Last updated on ClinicalTrials.gov
- June 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Brigham and Women's Hospital · Boston, MA
West Virginia · 1
- West Virginia University · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.